So I'll just quickly note the questions and answers that I got from Chris - it may be that others are interested:
1. As per the presentation slide, confirmed that 592 will not replace 591, but rather they are complementary treatments for different treatment stages
2. Regarding Telix's manufacturing capabilities, TLX has no interest in manufacturing products for other companies (the margins are just not there). Rather, it's purely so that they control their own manufacturing/vertical integration. Now there was more detail given on this answer, but that was the key point.
But as per others, I remain very impressed with this company, and hope that they do great things in terms of outcomes for patients.
Understanding Telix, page-908
-
- There are more pages in this discussion • 765 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$22.41 |
Change
0.210(0.95%) |
Mkt cap ! $7.500B | |||
| Open | High | Low | Value | Volume |
| $22.00 | $22.45 | $21.83 | $18.92M | 849.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2587 | $22.29 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $22.43 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/11/2024 (20 minute delay) ? |
| TLX (ASX) Chart |